Latest in News & Research
Skin of Color Underrepresented in AI Programs in Dermatology
Challenges in AI and its application to SOC stem from underrepresentation of SOC in datasets, issues with quality, standardization of images
Patients, Observers Tend to Favor 2-OCA Added to Wound Suture
No significant difference seen in scar cosmesis; patients favored 2-OCA for most components of wound care, although trends were not significant
Use of Immunohistochemistry in Melanoma Diagnosis Increased From 2000 to 2017
11 percent of melanoma cases had claims for ICH at or near diagnosis in 2000; this number increased to 51 percent in 2017
Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis
Investigator Global Assessment of 0 or 1 occurred in significantly more patients receiving tacrolimus microemulsion versus placebo
Margins >5 mm Often Needed to Achieve Tumor Clearance for Melanoma in Situ
Tumor location on cheek, larger preoperative size linked to requiring margins >5 mm to achieve tumor clearance
Alopecia Patients Willing to Accept Substantial Risks for Hair Regrowth
Adults willing to accept mean three-year risk for serious infection, cancer, blood clots of 7.4, 2.5, and 9.3 percent, respectively
Phototherapy for Vitiligo: An Overview of the Essentials
With an expanding array of therapeutic options emerging for vitiligo, phototherapy remains a safe and effective option
Delayed Melanoma Care During Pandemic Proved Costly
Delayed diagnoses due to pandemic lockdowns tied to years of life lost
LAUNCH ALERT: Lifileucel (AMTAGVI) Approved for Treatment of Advanced Melanoma
FDA grants accelerated approval for the first T cell therapy for a solid tumor cancer
Efficacy, Safety of Deucravacitinib Maintained Through Two Years
Exposure-adjusted incidence rates similar at one, two years for adverse events in patients with moderate-to-severe plaque psoriasis
Risk for Subsequent Squamous Cell Carcinomas Rises With Number of Prior Ones
Median time interval after the previous cutaneous squamous cell carcinoma decreases after each subsequent cutaneous squamous cell carcinoma
Clinical Markers Improve With IV Ertapenem for Hidradenitis Suppurativa
Significant reductions seen in mean Physician Global Assessment scores and in pain, C-reactive protein, IL-6, leukocytes
Deep Learning Improves Diagnostic Accuracy for Skin Diseases
Both specialists and generalists were 4 percentage points less accurate for diagnosis of images of dark versus light skin
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
sNDA is supported by positive data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials and interim results from the Phase 3...
FDA Approves Aurlumyn for Severe Frostbite
Newly approved medication lowers the need for amputation of fingers or toes
Study Looks at Access to U.S. Burn Centers Using 2019 Data
Disparities seen in access to burn centers, with lower access in the South and West and for those with lower income
Can Apremilast Improve Signs, Symptoms of Genital Psoriasis?
More patients receiving apremilast achieved modified static Physician Global Assessment of Genitalia response at week 16
Many Survivors of Localized Melanoma Fear Recurrence
Thirty-eight of 51 survivors had FCRI-SF score above the threshold for clinical fear of cancer recurrence
Smoking Linked to Melanoma-Associated Death in Early-Stage Melanoma
Greatest increased risk for melanoma-specific mortality seen for patients with SLNB-negative disease
Health Care Costs, Resource Utilization Increased for Vitiligo Patients
Differences in all-cause, vitiligo-related health care costs remained higher for those on treatments with systemic effects/mental health diagnoses
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide
myDermRecruiter and Dermsquared™ Announce Exclusive Partnership to Revolutionize Dermatology Career Advancement
For Immediate Distribution & Release
Metformin Use Not Significantly Linked to Pruritus
Canagliflozin significantly more likely to cause pruritus than insulin lispro or insulin glargine
24 of 1274